Excess return on book · base FY26
INFLUX HEALTHTECH LIMITED
This note states the assumptions and the arithmetic of one model of INFLUX HEALTHTECH LIMITED, built on its filed FY26 consolidated statements. The value is the outcome of the assumptions below and nothing else; it is not a fair value, a target or a recommendation.
Assumptions
| Input | This model | Filed reference |
|---|---|---|
| Return on opening book equity | 12% a year | FY26 ROE —% |
| Payout | 0% of profit | FY26 —% |
| Cost of equity | 13.49% (Rf 5.08, β 1.15, ERP 7.31) | 1-yr beta 1.15 |
| Terminal growth | 5% flat | — |
| Net debt · non-controlling interest · non-operating investments | ₹(25) · ₹0 · ₹0 cr | FY26 net debt ₹(25) cr |
| Shares | 2.32 crore | 2.32 crore today |
From enterprise to equity
| Book equity, FY26 | 0 |
| PV of 5 years of excess return | 0 |
| PV of the terminal excess return | — |
| less non-controlling interest | 0 |
| add non-operating investments | 0 |
| Equity value | — |
| ÷ 2.32 crore shares | ₹— |
Statement
This note is the reader's own model over publicly filed information: SEBI results XBRL filed with BSE and NSE and exchange price data, assembled by MarketPing software; every assumption above is the reader's. It contains no research recommendation, no price target and no opinion by MarketPing on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Historical per-share figures are on the current share count. Where a figure is unavailable the table shows a dash rather than an estimate. Nothing here constitutes investment advice, an offer or a solicitation.